Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Cited by (1,041)

Items 801–900 of 1,041

1. BRCA mutation in ovarian cancer: testing, implications and treatment considerations
   Robert T. Neff, Leigha A. Senter, Ritu Salani · 2017 · Therapeutic Advances in Medical Oncology
2. Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
   Iris Z. Uras, Herwig Peter Moll, Emilio Casanova · 2020 · International Journal of Molecular Sciences
3. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
   Benjamin Besse, Elvire Pons Tostivint, Keunchil Park, Sylvia Hartl, Patrick M. Forde, Maximilian Johannes Hochmair, Mark Magdi Awad, Michael Thomas, Glenwood D. Goss, Paul Wheatley‐Price et al. · 2024 · Nature Medicine
4. The biological underpinnings of therapeutic resistance in pancreatic cancer
   Gregory Lawrence Beatty, Gregor Werba, Costas Andreas Lyssiotis, Diane M. Simeone · 2021 · Genes & Development
5. Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells
   Bajrami, Ilirjana, Kigozi, Asha, Van Weverwijk, Antoinette, Brough, Rachel, Frankum, Jessica, Lord, Christopher J., Ashworth, Alan · 2012 · EMBO Molecular Medicine
6. Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function
   Felix Yi-Chung Feng, Johann Sebastian De Bono, Mark A. Rubin, Karen E. Knudsen · 2015 · Molecular Cell
7. PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy
   Paweł Domagała, Tomasz Huzarski, Jan Lubiński, Karol Gugała, W Domagała · 2011 · Breast Cancer Research and Treatment
8. The lysine‐specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer
   Theodoros N Rampias, Dimitris Karagiannis, Margaritis Avgeris, Alexander Polyzos, Antonis Kokkalis, Zoi Kanaki, Evgenia Kousidou, Maria Tzetis, Emmanouil Kanavakis, KONSTANTINOS G. STRAVODIMOS et al. · 2019 · EMBO Reports
9. Molecular subtypes and precision treatment of triple-negative breast cancer
   Shen Zhao, Wen‐Jia Zuo, Zhi‐Ming Shao, Yizhou Jiang · 2020 · Annals of Translational Medicine
10. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131
    Ingrid A. Mayer, Fengmin Zhao, Carlos L. Arteaga, W. Fraser Symmans, Ben Ho Park, Brian Leslie Burnette, Amye Juliet Tevaarwerk, Sofia F. Garcia, Karen Lisa Smith, Della Makower et al. · 2021 · Journal of Clinical Oncology
11. Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing
    McManus, Kirk J., Barrett, Irene J., Nouhi, Yasaman, Hieter, Philip · 2009 · Proceedings of the National Academy of Sciences
12. Platinum resistance in breast and ovarian cancer cell lines
    Niels Eckstein · 2011 · Journal of Experimental & Clinical Cancer Research
13. Metastatic Triple-negative Breast Cancer
    Emad A. Rakha, Stephen Y.T. Chan · 2011 · Clinical Oncology
14. Secondary mutations of BRCA1/2 and drug resistance
    Kiranjit K. Dhillon, Elizabeth M. Swisher, Toshiyasu Taniguchi · 2010 · Cancer Science
15. A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance
    Raphaël Ceccaldi, Kevin W. O’Connor, Kent William Mouw, Adam Y. Li, Ursula A. Matulonis, Alan D. D’Andrea, Panagiotis A. Konstantinopoulos · 2015 · Cancer Research
16. PARP-1 Regulates Metastatic Melanoma through Modulation of Vimentin-induced Malignant Transformation
    María Isabel Rodríguez, Andreína Peralta-Leal, Francisco O’Valle, José Manuel Rodríguez-Vargas, Ariannys González-Flores, Jara Majuelos‐Melguizo, Laura López, Santiago Serrano, Antonio Garcı́a de Herreros, Juan Carlos Rodrı́guez-Manzaneque et al. · 2013 · PLoS Genetics
17. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions
    Spyridon P. Basourakos, Likun Li, Ana M. Aparicio, Paul Gettys Corn, Jeri Kim, Timothy C. Thompson · 2016 · Current Medicinal Chemistry
18. Targeting DNA repair pathway in cancer: Mechanisms and clinical application
    Manni Wang, Siyuan Chen, Danyi Ao · 2021 · MedComm
19. Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA -Mutant Ovarian Cancer
    Shivaani Kummar, Amit M. Oza, Gini F. Fleming, Daniel M. Sullivan, David R. Gandara, Michael J. Naughton, Miguel Angel Villalona-Calero, Robert J. Morgan, Péter Szabó, Ahrim Youn et al. · 2015 · Clinical Cancer Research
20. Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51
    Ambber Ward, Kum Kum Khanna, Adrian P. Wiegmans · 2014 · Cancer Treatment Reviews
21. Improving efficacy of hyperthermia in oncology by exploiting biological mechanisms
    Nathalie van den Tempel, Michael R. Horsman, Roland Kanaar · 2016 · International Journal of Hyperthermia
22. An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
    Joaquı́n Mateo, Víctor Moreno, Avinash Gupta, Stanley B. Kaye, Emma Jane Dean, Mark Ross Middleton, Michael Leonard Friedlander, Charlie Gourley, Ruth Plummer, Gordon J.S. Rustin et al. · 2016 · Targeted Oncology
23. Current status of poly(ADP-ribose) polymerase inhibitors and future directions
    Akihiro Ohmoto, Shinichi Yachida · 2017 · OncoTargets and Therapy
24. A PET imaging agent for evaluating PARP-1 expression in ovarian cancer
    Mehran Makvandi, Austin R. Pantel, Lauren Ende Schwartz, Erin K. Schubert, Kuiying Xu, Chia‐Ju Hsieh, Catherine Hou, Hyoung Kim, Chi-Chang Weng, Harrison David Winters et al. · 2018 · Journal of Clinical Investigation
25. Progress towards a clinically-successful ATR inhibitor for cancer therapy
    Francis Mprah Barnieh, Paul M. Loadman, Robert A. Falconer · 2021 · Current Research in Pharmacology and Drug Discovery
26. Interferons and the immunogenic effects of cancer therapy
    Minn, Andy J. · 2015 · Trends in Immunology
27. JMJD1C demethylates MDC1 to regulate the RNF8 and BRCA1–mediated chromatin response to DNA breaks
    Sugiko Watanabe, Kenji Watanabe, Vyacheslav Akimov, Jiřina Bártková, Blagoy Blagoev, Jiri Lukas, Jiří Bártek · 2013 · Nature Structural & Molecular Biology
28. Inhibition of poly(ADP-ribosyl)ation in cancer: Old and new paradigms revisited
    Barbara Lupo, Livio Trusolino · 2014 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
29. Bridging of DNA breaks activates PARP2–HPF1 to modify chromatin
    Silvija Bilokapić, Marcin J. Suskiewicz, Ivan Ahel, Mario Halić · 2020 · Nature
30. CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer
    Takuya Tsujino, Tomoaki Takai, Kunihiko Hinohara, Fu Gui, Takeshi Tsutsumi, Xiao Feng Bai, Chenkui Miao, Chao Feng, Bin Gui, Zsófia M. Sztupinszki et al. · 2023 · Nature Communications
31. Integrated genomic analyses of ovarian carcinoma
    The Cancer Genome Atlas Research Network · 2011 · Nature
32. Molecular mechanisms of temozolomide resistance in glioblastoma multiforme
    Tor-Christian Aase Johannessen, Rolf Bjerkvig · 2012 · Expert Review of Anticancer Therapy
33. PARP inhibitors in ovarian cancer
    Jonathan Andrew Ledermann · 2016 · Annals of Oncology
34. Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors
    Xiumei Huang, Edward A. Motea, Zachary Moore, Jun Yao, Ying Dong, Gaurab Chakrabarti, Jessica A. Kilgore, Molly A. Silvers, Praveen L. Patidar, Agnieszka Cholka et al. · 2016 · Cancer Cell
35. PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer
    Jill J.J. Geenen, Sabine C. Linn, Jos H. Beijnen, Jan H.M. Schellens · 2017 · Clinical Pharmacokinetics
36. Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes
    Solène De Talhouet, Julien Péron, Aurélie Vuilleumier, Alex Friedlaender, Valeria Viassolo, Aurélie Ayme, Alexandre Bodmer, Isabelle Treilleux, Noémie Lang, Jean Christophe Tille et al. · 2020 · Scientific Reports
37. Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2 - and Non– BRCA1/2 -Mutant Cancers
    Timothy Anthony Yap, Rebecca Sophie Kristeleit, Vasiliki Michalarea, Stephen J. Pettitt, Joline S.J. Lim, Suzanne Carreira, Desamparados Roda, Rowan E. Miller, Ruth Riisnaes, Susana Miranda et al. · 2020 · Cancer Discovery
38. Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers
    Dominik Głodzik, Ana Bosch, Johan Hartman, Mattias Aine, Johan Vallon‐Christersson, Christel Reuterswärd, Anna Karlsson, Shamik Mitra, Emma Niméus, Karolina Holm et al. · 2020 · Nature Communications
39. DNA Repair: From Genome Maintenance to Biomarker and Therapeutic Target
    Shadia Ibrahim Jalal, Jennifer N. Earley, John J. Turchi · 2011 · Clinical Cancer Research
40. Sensitization to Radiation and Alkylating Agents by Inhibitors of Poly(ADP-ribose) Polymerase Is Enhanced in Cells Deficient in DNA Double-Strand Break Repair
    Dana A. Löser, Atsushi Shibata, A. Shibata, Lisa J. Woodbine, Penny Ann Jeggo, Anthony J. Chalmers · 2010 · Molecular Cancer Therapeutics
41. Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53
    Chris T. Williamson, Eiji Kubota, Jeffrey D. Hamill, Alexander C. Klimowicz, Ruiqiong Ye, Huong Muzik, Michelle Liane Dean, LiRen Tu, David P. Gilley, Anthony M. Magliocco et al. · 2012 · EMBO Molecular Medicine
42. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
    Aniello Cerrato, Francesco Morra, Angela Celetti · 2016 · Journal of Experimental & Clinical Cancer Research
43. TIRR regulates 53BP1 by masking its histone methyl-lysine binding function
    Pascal Drané, Marie Eve Brault, Gaofeng Cui, Khyati A. Meghani, Shweta Chaubey, Alexandre Detappe, Nishita Parnandi, Yizhou Joseph He, Xiao-Feng Zheng, Maria Victoria Botuyan et al. · 2017 · Nature
44. Precision medicine: the foundation of future cancer therapeutics
    Seung Ho Shin, Ann M. Bode, Zigang Dong · 2017 · npj Precision Oncology
45. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study
    Talia Golan, Maria Raitses‐Gurevich, Robin Kate Kelley, Andrea Grace Bocobo, Ayelet Borgida, Rachna T. Shroff, Spring Holter, Steve Gallinger, Daniel H. Ahn, Dan Aderka et al. · 2017 · The Oncologist
46. Latest clinical evidence and further development of PARP inhibitors in ovarian cancer
    Mansoor Raza Mirza, Sandro Pignata, Jonathan Andrew Ledermann · 2018 · Annals of Oncology
47. Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
    Stergios Boussios, Peeter Karihtala, Michele Moschetta, Afroditi Karathanasi, Agne Sadauskaite, Elie Rassy, Nicholas A. Pavlidis · 2019 · Diagnostics
48. Timeless Interacts with PARP-1 to Promote Homologous Recombination Repair
    Si Xie, Oliver Mortusewicz, Hoi Tang Ma, Patrick Herr, Randy Y.C. Poon, Thomas Helleday, Chengmin Qian · 2015 · Molecular Cell
49. BRCA1 gene: function and deficiency
    Miho Takaoka, Yoshio Miki · 2017 · International Journal of Clinical Oncology
50. Cytotoxic lymphocytes target characteristic biophysical vulnerabilities in cancer
    María Tello‐Lafoz, Katja Srpan, Elisa E. Sanchez, Jing Ying Hu, Ján Remšík, Yevgeniy Romin, Annalisa Calò, Douglas Robert Hoen, Umesh Kumar Bhanot, Luc G.T. Morris et al. · 2021 · Immunity
51. Lidocaine: A Local Anesthetic, Its Adverse Effects and Management
    Entaz Bahar, Hyonok Yoon · 2021 · Medicina
52. Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma
    Yoshimoto, Koji, Mizoguchi, Masahiro, Hata, Nobuhiro, Murata, Hideki, Hatae, Ryusuke, Amano, Toshiyuki, Nakamizo, Akira, Sasaki, Tomio · 2012 · Frontiers in Oncology
53. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer
    Martin David Forster, Konstantin Johannes Dedes, Shahneen Kaur Sandhu, Sophia Frentzas, Rebecca Sophie Kristeleit, Alan Ashworth, Christopher John Poole, Britta Weigelt, Stan B. Kaye, Lulama Rhoda Molife · 2011 · Nature Reviews Clinical Oncology
54. DNA end resection by CtIP and exonuclease 1 prevents genomic instability
    Wassim Eid, Martin Steger, Mahmoud El‐Shemerly, Lorenza P. Ferretti, Javier Peña-Dı́az, Christiane König, Emanuele Valtorta, Alessandro A. Sartori, Stefano Maria Ferrari · 2010 · EMBO Reports
55. Mapping genetic interactions in human cancer cells with RNAi and multiparametric phenotyping
    Christina Laufer, Bernd Fischer, Maximilian Billmann, Wolfgang K. Huber, Michael Boutros · 2013 · Nature Methods
56. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations
    Nicholas Pulliam, Fang Fang, Ali Özeş, Jessica Tang, Adeoluwa Adewuyi, Harold N Keer, John F. Lyons, Stephen B. Baylin, Daniela Elena Matei, Harikrishna Nakshatri et al. · 2018 · Clinical Cancer Research
57. Role of PARP Inhibitors in Cancer Biology and Therapy
    Diwakar Davar, Jan Hendrik Beumer, Lana Hamieh, Hussein Abdul-Hassan Tawbi · 2012 · Current Medicinal Chemistry
58. MiR-96 Downregulates REV1 and RAD51 to Promote Cellular Sensitivity to Cisplatin and PARP Inhibition
    Yemin Wang, Jen‐Wei Huang, Philamer C. Calses, Christopher J. Kemp, Toshiyasu Taniguchi · 2012 · Cancer Research
59. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy
    X Bian, Jing Gao, F Luo, Ceng Rui, T Zheng, Dong‐Yu Wang, Y Wang, Thomas M. Roberts, Pengcong Liu, Jean J. Zhao et al. · 2017 · Oncogene
60. Role of Rad51 and DNA repair in cancer: A molecular perspective
    Erik Laurini, Domenico Marson, Alice Fermeglia, Suzana Aulić, Maurizio Fermeglia, Sabrina Pricl · 2020 · Pharmacology & Therapeutics
61. BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies
    Xiaoyu Fu, Wei Tan, Qibin Song, Huadong Pei, Juanjuan Li · 2022 · Frontiers in Cell and Developmental Biology
62. PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy
    Erica Salvati, Marco Scarsella, Manuela Porru, Angela Rizzo, Sara Iachettini, Lucio Tentori, Grazia Graziani, Maurizio D’Incalci, Malcolm F. G. Stevens, Augusto Orlandi et al. · 2010 · Oncogene
63. Cyclin-Dependent Kinase 2 Functions in Normal DNA Repair and Is a Therapeutic Target in BRCA1-Deficient Cancers
    Andrew J. Deans, Kum Kum Khanna, Carolyn J. McNees, Ciro Mercurio, Jörg Heierhorst, Grant A. McArthur · 2006 · Cancer Research
64. The trans cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1/2-deficient cells
    Antoine Simoneau, Rosalinda Xiong, Lee Zou · 2021 · Genes & Development
65. Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers
    Guoyan Liu, Da Yang, Rajesha Rupaimoole, Chad Victor Pecot, Yan Sun, Lingegowda Selanere Mangala, Xia Li, Ping Ji, David E. Cogdell, Limei Hu et al. · 2015 · JNCI Journal of the National Cancer Institute
66. Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines
    Eiji Kubota, Christopher T Williamson, Ruiqiong Ye, Anifat A. Elegbede, Lars Peterson, Susan P. Lees‐Miller, Dafydd Gwyn Bebb · 2014 · Cell Cycle
67. The macro domain protein family: Structure, functions, and their potential therapeutic implications
    Weidong Han, Xiaolei Li, Xiaobing Fu · 2011 · Mutation Research/Reviews in Mutation Research
68. The recognition and removal of cellular poly( ADP ‐ribose) signals
    Eva Barkauskaite, Gytis Jankevicius, Andreas G. Ladurner, Ivan Ahel, Gyula Timinszky · 2013 · FEBS Journal
69. REV1 and polymerase ζ facilitate homologous recombination repair
    Shilpy Sharma, James Kevin Hicks, Colleen L. Chute, Julia R. Brennan, Joon-Young Ahn, Thomas W. Glover, Christine E. Canman · 2011 · Nucleic Acids Research
70. DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
    Ana Osório, Roger Laughlin Milne, Karoline B. Kuchenbaecker, Tereza Vaclová, Guillermo Pita, Rosario Alonso, Paolo Peterlongo, Ignacio Blanco, Miguel de la Hoya, Mercedes Duran et al. · 2014 · PLoS Genetics
71. Combined Hyperthermia and Radiotherapy for the Treatment of Cancer
    Punit Kaur, Mark Hurwitz, Sunil Krishnan, Alexzander A. A. Asea · 2011 · Cancers
72. Sensitivity to Poly(ADP-ribose) Polymerase (PARP) Inhibition Identifies Ubiquitin-specific Peptidase 11 (USP11) as a Regulator of DNA Double-strand Break Repair
    Timothy D. Wiltshire, Courtney A. Lovejoy, Tong Wang, Fen Xia, Mark J. O’Connor, David Cortez · 2010 · Journal of Biological Chemistry
73. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
    Emma Jane Dean, Mark Ross Middleton, Thinn P. Pwint, Helen Swaisland, J Carmichael, P. Goodege, Malcolm Ranson · 2012 · British Journal of Cancer
74. DNA double-strand break repair pathways, chromosomal rearrangements and cancer
    Torben Kasparek, Timothy C. Humphrey · 2011 · Seminars in Cell and Developmental Biology
75. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective
    Shahneen Kaur Sandhu, Timothy Anthony Yap, Johann Sebastian De Bono · 2009 · European Journal of Cancer
76. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib
    Chen Wang, Nicholas Jette, Daniel Moussienko, Dafydd Gwyn Bebb, Susan P. Lees‐Miller · 2017 · Translational Oncology
77. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer
    Hirohiko YAMAGUCHI, Yi Du, Katsuya Nakai, Ming Ding, S.H. Chang, J L Hsu, Jing Yao, Yue Wei, L Nie, S Jiao et al. · 2017 · Oncogene
78. A chemoproteomic portrait of the oncometabolite fumarate
    Rhushikesh A. Kulkarni, Daniel W. Bak, Darmood Wei, Sarah E. Bergholtz, Chloe A. Briney, Jonathan H. Shrimp, Aktan Alpsoy, Abigail L. Thorpe, Arissa E. Bavari, Daniel R. Crooks et al. · 2019 · Nature Chemical Biology
79. Combinatorial CRISPR screen identifies fitness effects of gene paralogues
    Nicola Thompson, Marco Ranzani, Louise van der Weyden, Vivek Iyer, Victoria Offord, Alastair Droop, Fiona M. Behan, Emanuel Gonçalves, Anneliese O. Speak, Francesco Iorio et al. · 2021 · Nature Communications
80. The expanding role of poly(ADP-ribose) metabolism: current challenges and new perspectives
    Jean‐Philippe Gagné, Michael J. Hendzel, Arnaud Droit, Guy G. Poirier · 2006 · Current Opinion in Cell Biology
81. The CIP2A–TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer
    Adam, Salomé, Rossi, Silvia Emma, Moatti, Nathalie, De Marco Zompit, Mara, Xue, Yibo, Ng, Timothy F., Álvarez-Quilón, Alejandro, Desjardins, Jessica, Bhaskaran, Vivek, Martino, Giovanni et al. · 2021 · Nature Cancer
82. Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program
    Malcolm Anders Smith, C. Patrick Reynolds, Min H. Kang, Edward Anders Kolb, Richard Greg Gorlick, Hernán Carol, Richard B. Lock, Stephen Thomas Keir, John M. Maris, Catherine A. Billups et al. · 2014 · Clinical Cancer Research
83. Functional Assays for Analysis of Variants of Uncertain Significance inBRCA2
    Lucia Guidugli, Aura Carreira, Sandrine M. Caputo, Åsa Ehlén, Alvaro Galli, Álvaro N.A. Monteiro, Susan L. Neuhausen, Thomas van Overeem Hansen, Fergus J. Couch, Maaike P.G. Vreeswijk · 2013 · Human Mutation
84. Chemotherapeutic Compounds Targeting the DNA Double-Strand Break Repair Pathways: The Good, the Bad, and the Promising
    Christian Jekimovs, Emma Bolderson, Amila Suraweera, Mark N. Adams, Kenneth John O'Byrne, Derek J. Richard · 2014 · Frontiers in Oncology
85. Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells
    Michele Cea, Antonia Cagnetta, Sophia Adamia, Chirag Acharya, Yu‐Tzu Tai, Mariateresa Fulciniti, Hiroto Ohguchi, Aditya Munshi, Prakrati C. Acharya, Manoj Bhasin et al. · 2015 · Blood
86. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair
    Fumi Higuchi, Hiroaki Nagashima, Jianfang Ning, Mara V.A. Koerner, Hiroaki Wakimoto, Daniel P. Cahill · 2020 · Clinical Cancer Research
87. Classification of four distinct osteoarthritis subtypes with a knee joint tissue transcriptome atlas
    C. Yuan, Zong-You Pan, Kun Zhao, Jun Li, Zi-Xuan Sheng, Xudong Yao, Hua Liu, Xiaolei Zhang, Yang Yang, Dongsheng Yu et al. · 2020 · Bone Research
88. Recent advances in DDR (DNA damage response) inhibitors for cancer therapy
    Binbin Cheng, Wei Pan, Yi Xing, Yao Xiao, Jianjun Chen, Zheng Xu · 2022 · European Journal of Medicinal Chemistry
89. Mechanism-based design of agents that selectively target drug-resistant glioma
    Kingson Lin, Susan E. Gueble, Ranjini K. Sundaram, Eric D. Huseman, Ranjit S. Bindra, Seth B. Herzon · 2022 · Science
90. Synthesis, Biological Evaluation, and Structure–Activity Relationships of a Novel Class of Apurinic/Apyrimidinic Endonuclease 1 Inhibitors
    Ganesha Rai, Vaddadi N. Vyjayanti, Dorjbal G. Dorjsuren, Anton M. Simeonov, Ajit Jadhav, David M. Wilson, David J. Maloney · 2012 · Journal of Medicinal Chemistry
91. Targeting DNA repair mechanisms in cancer
    John Michael Furgason, El Mustapha Bahassi · 2012 · Pharmacology & Therapeutics
92. Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers
    Johnathan A. Watkins, Daniel B. Weekes, Vandna Shah, Patrycja Gazińska, Shalaka Prakash Joshi, Bhavna Sidhu, Cheryl Gillett, Sarah E. Pinder, Fabio Vanoli, Maria Jasin et al. · 2015 · Cancer Discovery
93. N-methylpurine DNA glycosylase and DNA polymerase β modulate BER inhibitor potentiation of glioma cells to temozolomide
    Jiang-bo Tang, David Svilar, Ram Narayan Trivedi, Xiaohong Wang, Eva M. Goellner, Briana Moore, Ronald L. Hamilton, Lauren A. Banze, Ashley R. Brown, Robert William Sobol · 2011 · Neuro-Oncology
94. Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer
    Manzoor Ahmad Mir, Hina Qayoom, Umar Mehraj, Safura Nisar, Basharat Ahmad Bhat, Nissar Ahmad Wani · 2020 · Current Cancer Drug Targets
95. Base excision repair and its implications to cancer therapy
    Gabrielle J. Grundy, Jason Luke Parsons · 2020 · Essays in Biochemistry
96. Emerging cancer therapeutic opportunities target DNA-repair systems
    Jian Ding, Ze‐Hong Miao, Linghua Meng, Meiyu Geng · 2006 · Trends in Pharmacological Sciences
97. Identifying druggable disease-modifying gene products
    Scott J. Dixon, Brent R. Stockwell · 2009 · Current Opinion in Chemical Biology
98. “Contextual” Synthetic Lethality and/or Loss of Heterozygosity: Tumor Hypoxia and Modification of DNA Repair
    Norman Hok Ling Chan, Robert Glen Bristow · 2010 · Clinical Cancer Research
99. Hereditary Breast Cancer: Clinical, Pathological and Molecular Characteristics
    Martin Jakob Larsen, Mads Thomassen, Anne‐Marie Gerdes, Torben Arvid Kruse · 2014 · Breast Cancer Basic and Clinical Research
100. Update on PARP Inhibitors in Breast Cancer
     Alexandra S. Zimmer, Mitchell Gillard, Stanley Lipkowitz, Jung‐Min Lee · 2018 · Current Treatment Options in Oncology